Table 3. Description of 15 cases of primary lung cancer confirmed after positive screening.

Sex, Age (years)	Lung-RADS	Histology	TNM	Staging	Treatment
Positive screening (first round)
Female, 59	4X	Adenocarcinoma	cT3 cN3 M1c	IVB	Chemotherapy
Female, 72	4A	Adenocarcinoma	pT1pN0M0	IA	Surgery
Female, 64	4A	Adenocarcinoma	pT1cN0M0	IA3	Surgery
Male, 63	4X	Adenocarcinoma	cT1b cN0 M0	IA2	Radiotherapy, curative intent (VMAT)
Female, 58a	4A	Adenocarcinoma	T1aN2M1c	IVB	Palliative radiotherapy
Female, 78	4B	Adenocarcinoma	cT1b cN0 M0	IA2	Surgery
Female, 61	4X	Small cell carcinoma	-	Extensive disease	? (oncology evaluation outside the screening center)
Female, 74	4B	Poorly differentiated carcinoma (probable squamous cell carcinoma)	cT3 CN3 M1b	IVA	Chemotherapy + targeted therapy (research protocol)
Female, 63	4B	Adenocarcinoma	pT3pN0M0	IIB	Surgery
Male, 77	4B	Adenocarcinoma	cT2aN0M0	IB	Initially refused treatment. Subsequent treatment outside the center.
Female, 55	4B	Adenocarcinoma	pT2aN0M0	IB	Surgery
Positive screening (second round)
Male, 71	4B	Adenocarcinoma	pT1b pN0 M0	IA2	Surgery
Female, 55b	4X	Adenocarcinoma	T3N3M1a	IVA	? (oncology evaluation outside the screening center)
Male, 60	4A	Adenocarcinoma	pT2apN0M0	IB	Surgery
Female, 56	4B	Adenocarcinoma	T2 cN2 M1c	IV	Chemotherapy

Lung-RADS: Lung CT Screening Reporting and Data System score; and VMAT: volumetric modulated arc therapy. ^aDiagnosis/staging delayed for 13 months. ^bDelay between control CT and further investigation (suggestion, 6 months; completion, 22 months). Note: One case of breast cancer metastasis was not included in this analysis.